Increase in eosinophil-derived neurotoxin level in school children with allergic disease

Chang-Keun Kim 1,*, Dong Yoon Kang 2, Zak Callaway 1,3, Kyoungh Seo Kim 4, Eun Mi Kwon 1, Fumiya Yamaide 5, Taiji Nakano 5, Yoichi Suzuki 6, Yoichi Mashimo 6, Akira Hata 6, Yoshitaka Okamoto 7,8, and Naoki Shimojo 9,*

1Asthma & Allergy Center, Department of Pediatrics, Inje University Sanggye Paik Hospital, Seoul, Korea
2Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea
3Department of Biomedical Science, School of Biological Sciences, University of Ulans, Ulans, Korea
4Department of Clinical Pharmacology and Therapeutics, Kyung Hee University School of Medicine, Seoul, Korea
5Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan
6Department of Public Health, Graduate School of Medicine, Chiba University, Chiba, Japan
7Department of Otorhinolaryngology and Head and Neck Surgery, Graduate School of Medicine, Chiba, Japan
8Chiba Rosia Hospital, Chiba, Japan
9Center for Preventive Medical Sciences, Chiba University, Chiba, Japan

ABSTRACT

Background: Eosinophils are major effector cells of allergic disease and excellent markers of eosinophilic inflammation. Accurate and reliable biomarkers are helpful in the diagnosis, treatment, and control of allergic disease.

Objective: This study aimed to investigate an alternate marker of eosinophilic inflammation, eosinophil-derived neurotoxin (EDN), in a number of allergic diseases.

Methods: Three hundred ninety-six elementary school-age children with various allergic conditions were recruited for this study. Subgroups included food allergies (FAs), atopic dermatitis (AD), bronchial asthma (BA), and allergic rhinitis (AR). EDN levels in these groups were compared to those in 93 healthy controls (HC).

Results: All subjects with allergic disease had elevated levels of serum EDN (median [interquartile range]: FA, 124.2 ng/mL [59.13–160.5 ng/mL]; AD, 110.8 ng/mL [57.52–167.9 ng/mL]; BA, 131.5 ng/mL [60.60–171.0 ng/mL]; AR, 91.32 ng/mL [46.16–145.0 ng/mL]) compared to HC (38.38 ng/mL [32.40–55.62 ng/mL]) (p < 0.0001). These elevated levels were consistent throughout the age range (6–12 years) of the healthy study subjects (p = 0.0679). EDN levels also correlated well with total immunoglobulin E (Rs = 0.5599, p < 0.0001). Looking at all individuals with an allergic disease, the area under the curve was 0.790.

Conclusions: Direct measures of eosinophilic inflammation are needed for accurate diagnosis, treatment, and monitoring of allergic diseases. EDN may be a worthy biomarker of eosinophil activity and a useful screening tool for allergic diseases including FA, AD, BA, and AR.

Keywords: Food allergy; Atopic dermatitis; Bronchial asthma; Allergic rhinitis; Biomarkers; Eosinophil-derived neurotoxin
INTRODUCTION

Eosinophils are major effector cells of the allergic process [1] and have proven to be the best marker of allergic inflammation. Activation of eosinophils leads to extracellular release of a number of granule proteins, such as eosinophil-derived neurotoxin (EDN) [2], and it is these granule proteins that have been the most strongly implicated in the pathophysiology of asthma [3].

EDN levels have been demonstrated to be an alternative measurement of the eosinophilic inflammation found in allergic disease [4-6]. It has been proposed that serum levels of degranulation products like EDN represent both the circulating levels and secretory activity of eosinophils [7]. Furthermore, several research groups have found EDN to be a more useful biomarker for evaluating disease severity than other degranulation products [8-10].

In this study, we aimed to compare EDN levels in a number of different groups of elementary school children with various allergic diseases: specifically, bronchial asthma (BA), atopic dermatitis (AD), allergic rhinitis (AR), and food allergy (FA).

MATERIALS AND METHODS

Subjects

Three hundred ninety-six elementary school-age children were recruited from an elementary school attached to Chiba University. Details of control subjects have been described previously [11] and can be found in Table 1 of this study. The study protocol was approved by the Committee on Human Research of Chiba University (IRB number: 0710). Informed consent was obtained from each of the study subjects and their guardians. BA diagnosis was made according to the ISAAC (International Study of Asthma and Allergies in Childhood) questionnaire. Concurrent physician-diagnosed AD, AR, and FA were assessed. Of the 250 children with any type of allergic disease, 27.6% had multiple allergic diseases. Children with no allergic disease and those not exhibiting serum specific immunoglobulin E (IgE) to house dust mites, cedar pollen or egg whites were defined as healthy children.

Inclusion criteria for allergic diseases included symptomatic or asymptomatic asthma or allergic diseases. Exclusion criteria included: any health condition that would affect the ability of the patient to give a blood specimen; or any potential for serious adverse events. None of the healthy children had a history of asthma or allergic diseases.

| Characteristic | Healthy controls (n = 93) | Four allergic disease subgroups |
|---------------|--------------------------|------------------------------|
|               |                          | Food allergies (n = 34) | Atopic dermatitis (n = 34) | Bronchial asthma (n = 39) | Allergic rhinitis (n = 143) |
| Age (yr)      |                          |                      |                             |                             |                             |
| Mean ± SD     | 8.9 ± 1.7                | 9.0 ± 1.8            | 9.4 ± 1.6                    | 9.3 ± 1.8                    | 9.5 ± 1.7                    |
| Median (range)| 9 (6–12)                | 9 (6–12)             | 10 (7–12)                    | 9 (7–12)                     | 10 (7–12)                    |
| Sex (male %)  | 36.30                    | 50.00                | 54.20                        | 69.20                        | 60.80                        |
| Serum IgE (IU/mL) | 34.8 ± 54.6           | 473.5 ± 683.9        | 478.7 ± 608.1                | 346.1 ± 304.2                | 308.6 ± 3,329.3              |
| Median (range) | 21.2 (5.0–108.0)        | 153.0 (5.8–2,150.0)  | 378.0 (13.2–1,160.0)         | 221.0 (29.1–1,080.0)         | 184.0 (7.5–1,020.0)          |

SD, standard deviation; IgE, Immunoglobulin E.
Blood specimen collection
BD Vacutainer (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) serum separation tubes were used to collect blood specimens. The tourniquet was removed from the arm as soon as blood flowed to prevent hemoconcentration. Care was taken to perform venipuncture in a manner so that the likelihood of any complication following this was minimized. The nurse performing the venipuncture observed universal precautions for the prevention of bloodborne pathogen transmission.

Serum EDN measurement
Serum specimens were prepared, as described by Peterson et al. [12]. Briefly, serum was prepared by allowing blood to clot at 25°C for 1 hour, then centrifuged at 1,350 g for 10 minutes at 4°C. Each serum specimen was aliquoted into a new plastic tube and stored at -70°C until the assay.

The central laboratory at Inje University Sanggye Paik Hospital in Seoul, Korea was used for serum EDN (sEDN) measurements. sEDN concentrations were measured using the K®EDN “sandwich” enzyme-linked immunosorbent assay (ELISA) [13] kit (SKIMS-BIO Co., Seoul, Korea), with results expressed in ng/mL. This ELISA detects human EDN with a minimum detection limit of 6.0 ng/mL, maximum detection limit of 400 ng/mL, and does not cross-react with eosinophil cationic protein (ECP). The method described by Morioka et al. [14] was followed but modified slightly. Briefly, Nunc MaxiSorp 96-well plates (Thermo Fisher Scientific, Waltham, MA, USA) were coated overnight at 4°C with 100 μL of mouse anti-EDN monoclonal antibody (mAb), diluted in phosphate-buffered saline (PBS). The wells were blocked overnight at 4°C with 200 μL of blocking buffer (1X PBS, 1% bovine serum albumin [BSA], 10% sucrose). Standard EDN was diluted with 50 mM tris pH 8.0 containing 0.05% Tween 20 buffer (Sigma-Aldrich, St. Louis, Mom USA), 0.15 M NaCl, and 0.5% BSA (termed assay diluent). The range of measurements was 0.6–40 ng/mL, indicating assay sensitivity was less than 0.6 ng/mL. Between each subsequent step, plates were washed 3 times in PBS containing 0.05% Tween 20. Samples were then diluted in 50 mM tris pH 8.0 containing 0.05% Tween 20, and 0.15 M NaCl. One-hundred microliter of standards and diluted samples were applied to the plates, and incubated at room temperature for 1 hour. After washing, 100 μL of horseradish-peroxidase-labeled mouse anti-EDN mAb was added to the wells and incubated at room temperature for 1 hour. After another washing, the peroxidase substrate tetramethylbenzidine (Sigma-Aldrich) was added (100 μL/well) and incubated for 10 minutes at room temperature. Enzyme reactions were stopped with 1N HCl (100 μL/well). Absorbance was measured at 450 nm by a Micro Plate Reader Infinite 200 PRO (TECAN, Männedorf, Switzerland). sEDN was determined from a dose response curve by multiplying the value read from the standard curve by the dilution factor.

Statistical analysis
Data are represented as mean ± standard deviation (SD) if normally distributed, or median and range if not normally distributed. Differences in subject characteristics were compared across subgroups with the chi-squared test or Fisher exact test for categorical variables, and analysis of variance with Scheffe post hoc test or Kruskal-Wallis test with Dunn post hoc test for continuous variables, as applicable. Normality tests for data distribution were performed using Shapiro-Wilk test. Univariate and multivariate logistic regression analyses were performed to identify prognostic factors that were independently associated with prolonged hospitalizations. A multivariate model was created using a backward elimination method, and the probability was set at 0.05 for removal. Odds ratio with 95% confidence interval
were calculated for prognostic factors associated with prolonged hospitalizations. The cutoff values for EDN statistics were based on 45 ng/mL. All statistical analyses were performed with IBM SPSS Statistics ver. 24.0 (IBM Co., Armonk, NY, USA) and a \( p \) value of <0.05 was considered statistically significant.

**RESULTS**

**Subject characteristics**

Baseline subject characteristics are displayed in Table 1. There were no significant differences in characteristics among the different groups.

**Serum levels of EDN**

Serum levels of EDN are shown in Fig. 1. Median (interquartile range) for each group were as follows: healthy controls (HC), 38.38 ng/mL (32.40–55.62 ng/mL); FA, 124.2 ng/mL (59.13–160.5 ng/mL); AD, 110.8 ng/mL (57.52–167.9 ng/mL); BA, 131.5 ng/mL (60.60–171.0 ng/mL); AR, 91.32 ng/mL (46.16–145.0 ng/mL). Comparing EDN levels in HC to the other groups showed significant differences: HC vs. FA (\( p < 0.0001 \)); HC vs. AD (\( p < 0.0001 \)); HC vs. BA (\( p < 0.0001 \)); HC vs. AR (\( p < 0.0001 \)).

Subgrouping EDN levels according to age in healthy subjects in Fig. 2, median (interquartile range) were as follows: age 6, 21.93 (18.38–34.49); age 7, 37.84 (32.40–52.18); age 8, 44.07 (36.24–62.54); age 9, 38.26 (28.45–53.80); age 10, 41.46 (31.99–56.40); age 11, 35.33 (28.16–67.72). There were no significant differences in serum EDN level among the age groups (\( p = 0.0679 \)).

There was good correlation (Rs = 0.5599, \( p < 0.001 \)) between sEDN level and total IgE (Fig. 3).

Fig. 1. Serum eosinophil-derived neurotoxin (EDN) levels in each study subgroup. Healthy controls (HC) exhibited significantly lower levels (\( p < 0.0001 \)) than all other subgroups with allergic disease: food allergy (FA), atopic dermatitis (AD), bronchial asthma (BA), and allergic rhinitis (AR).
Fig. 4 shows the area under the curve (AUC) for all allergic diseases in this study (i.e., FA, AD, BA, and AR). The true positive rate (aka sensitivity) (proportion of those patients with an elevated sEDN level that also have an allergic disease) was plotted on the y axis, while the false positive rate (aka 1 – specificity) (1 – proportion of those patients with a normal sEDN level that do not have an allergic disease) was plotted on the x axis. The AUC from an receiver operating characteristic curve analysis of serum EDN for all allergic diseases (FA, AD, BA, and AR) was 0.790 with 81.2% sensitivity and 69.8% specificity.

Fig. 2. Eosinophil-derived neurotoxin (EDN) level according to age. No significant difference ($p = 0.0679$) in EDN level among all age groups.

Fig. 3. Correlation between total immunoglobulin E (IgE) and eosinophil-derived neurotoxin (EDN) level ($Rs = 0.5599; p < 0.0001$).
DISCUSSION

Measuring sEDN levels in school-age children with physician-diagnosed allergic disease and comparing these levels to healthy children of the same age, we found significant elevation of EDN in those with disease. Adding our findings to those of previous studies on EDN and allergic disease, we can conclude that EDN is a good biomarker for eosinophilic inflammation and may be useful as a screening tool.

Diagnosis of allergic disease in young children is a difficult task. Assessment of symptoms and airway function have traditionally been used to diagnose, treat, and control allergic disease such as asthma [15, 16]. However, it is especially difficult to test airway function in young children because of their inability to participate in the various tests. Furthermore, the use of these traditional markers of airway inflammation is tenous due in part to the fact that airway function and symptoms can be temporarily improved by bronchodilators with no concomitant control of inflammation [17]. Persistent inflammation has been conclusively demonstrated in patients treated according to symptoms and lung function [18]. The sEDN levels measured in our test groups reflect this. Healthy children with no diagnosed allergic disease measured at a median of 38.38 ng/mL, significantly lower than levels found in children with FAs (124.2 ng/mL), AR (91.32 ng/mL), BA (131.5 ng/mL), or allergic dermatitis (110.8 ng/mL). In previous studies [10], our research group found EDN levels to be predictive for asthma. Using 44.2 ng/mL (median ± 1SD) as the cutoff for an elevated EDN level compared to those found in HC, sensitivity was 81.3%, specificity was 87.1%, positive predictive value was 90.7%, and negative predictive value was 75.0% [4]. It has been suggested that the secretory activity of eosinophils—a combination of concentration of eosinophils and their propensity to release degranulation products—may be a key marker of disease activity, and is more accurately measured by eosinophil degranulation products such as EDN [7].

In our study, we investigated sEDN levels in children from 6 to 12 years of age. When our study subjects were separated according to age, there was no significant difference in EDN level. This suggests that using EDN level as a biomarker for screening (i.e., diagnosis),
treatment, and monitoring could be useful throughout childhood [19]. There have also been several studies of sEDN levels in children 6 and under and with a variety of conditions, including asthma, AD, AR, and FA. For example, a recently published study [5] of children aged 1 to 6 with asthma (beta2-agonist responsive recurrent and multiple trigger wheeze) and parental asthma or physician-diagnosed AD, AR, or FA found a majority of recruited subjects had elevated levels of sEDN (defined as ≥53 ng/mL). Furthermore, their EDN levels were used as a secondary outcome of treatment. Elevated sEDN levels in this age group have been found in other studies [4, 5, 10], as well. The utility of EDN as a biomarker in 6 and under children is especially important considering the difficulties of diagnosing, treating, and monitoring allergic disease in this age group.

As expected, total IgE correlated well with EDN level. IgE is one of the most important allergy biomarkers, as it is a major contributing factor in most types of allergic disease [20], including asthma, allergic dermatitis, AR, and IgE-mediated FA. Though asthma is a heterogeneous disease with many clinical subtypes, the classical IgE-associated asthma phenotype (also termed ‘extrinsic’) starting in childhood is the most widely studied, as it is the most common in real life and easily studied in the clinical laboratory [21]. As part of the ‘one airway, one disease’ hypothesis [22], it is believed rhinitis and asthma are 2 manifestations of a single syndrome, the chronic allergic respiratory syndrome, and it has been shown that one therapy can treat both diseases simultaneously [23, 24]. The correlation between the serum EDN level and the serum total IgE level is associated with an atopic status in elementary school-age children.

One of the key investigative goals of our study was to assess EDN as a biomarker for allergic activity in young children. As a group, EDN levels in our study subjects, who all had physician-diagnosed allergic disease, showed good sensitivity and specificity. It has been suggested by many that treatment based on inflammatory markers is more efficacious (i.e., reduces the frequency and severity of exacerbations) than treatment based on clinical symptoms and other traditional objective measures of lung function, such as peak expiratory flow and spirometry [25]. EDN is a more accurate reflection of eosinophil activity than merely counting eosinophil numbers, and EDN is a more easily recoverable degranulation product than ECP because ECP is sticky (i.e., sticks to tube walls) and a more highly charged protein [26].

Knowing both the inflammatory profile and the clinical categorization of the patient develops a clearer phenotype of the allergic disease patient and appears to contribute to improved care. Using a more accurate biomarker of eosinophilic inflammation, such as EDN, in disease management may produce even better results.

ACKNOWLEDGEMENTS

This research was partly funded by a 2018 Inje University Industry-Academia Collaboration Foundation grant.

REFERENCES

1. Busse WW, Rosenwasser LJ. Mechanisms of asthma. J Allergy Clin Immunol 2003;111:S799-804. PUBLMED | CROSSREF
2. Moqbel R, Lace P, Adamko DJ, Odemuyiwa SO. Biology of eosinophils. In: Adkinson NF Jr, Bochner BS, Busse WW, Holgate ST, Lemanske Jr RF, Simons FER, editors. Allergy: principles & practice. St. Louis: Mosby; 2008. p. 295-310.

3. Gleich GJ, Adolphson CR. The eosinophil and bronchial asthma: evidence for a critical role of eosinophils in pathophysiology. In: Sanderson CJ, editor. Interleukin-5: from molecule to drug target for asthma, (lung biology in health and disease). New York: Marcel Dekker, Inc.; 1999. p. 1-37.

4. Kim CK, Callaway Z, Park JS, Kwon EM. Utility of serum eosinophil-derived neurotoxin (EDN) measurement by ELISA in young children with asthma. Allergol Int 2017;66:70-4.

5. Kim CK, Callaway Z, Park JS, Nishimori H, Ogino T, Nagao M, Fujisawa T. Montelukast reduces serum levels of Eosinophil-Derived Neurotoxin in preschool asthma. Allergy Asthma Immunol Res 2018;10:686-97.

6. Kim CK, Seo IK, Ban SH, Fujisawa T, Kim DW, Callaway Z. Eosinophil-derived neurotoxin levels at 3 months post-respiratory syncytial virus bronchiolitis are a predictive biomarker of recurrent wheezing. Biomarkers 2013;18:230-5.

7. Venge P. Monitoring the allergic inflammation. Allergy 2004;59:26-32.

8. Kim KW, Lee KE, Kim ES, Song TW, Sohn MH, Kim KE. Serum eosinophil-derived neurotoxin (EDN) in diagnosis and evaluation of severity and bronchial hyperresponsiveness in childhood asthma. Lung 2007;185:97-403.

9. Taniuchi S, Chihara J, Koijima T, Yamamoto A, Sasai M, Kobayashi Y. Serum eosinophil derived neurotoxin may reflect more strongly disease severity in childhood atopic dermatitis than eosinophil cationic protein. J Dermatol Sci 2001;26:79-82.

10. Kim CK, Callaway Z, Fletcher R, Koh YY. Eosinophil-derived neurotoxin in childhood asthma: correlation with disease severity. J Asthma 2010;47:568-73.

11. Suzuki Y, Hattori S, Mashino Y, Funamizu M, Kohno Y, Okamoto Y, Hata A, Shimojo N. CD14 and IL4R gene polymorphisms modify the effect of day care attendance on serum IgE levels. J Allergy Clin Immunol 2009;123:1408-11.e1.

12. Peterson CG, Enander I, Nystrand J, Anderson AS, Nilsson L, Venge P. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy 1991;21:561-7.

13. Murphy KR. The detection, measurement, and characterization of antibodies, and their use as research and diagnostic tools. In: Murphy K. Janeway’s Immunobiology. 8th ed. New York: Garland Science; 2012.

14. Morioka J, Kurosawa M, Inamura H, Nakagami R, Mizushima Y, Chihara J, Yokoseki T, Kitamura S, Omura Y, Shibata M. Development of a novel enzyme-linked immunosorbent assay for blood and urinary eosinophil-derived neurotoxin: a preliminary study in patients with bronchial asthma. Int Arch Allergy Immunol 2000;122:49-57.

15. The Global Initiative for Asthma. GINA report, global strategy for asthma management and prevention [Internet]. Fontana (WI): The Global Initiative for Asthma; 2020 [cited 2021 Jan 1]. Available from: http://www.ginasthma.org/gina-reports

16. British Thoracic Society. BTS/SIGN British guideline on the management of asthma [Internet]. London: British Thoracic Society; 2021 [cited 2019 Dec 1]. Available from: https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/

17. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000;161:64-72.

18. Sont JI, Han J, van Krieken JM, Evertse CE, Hooijer R, Willems LN, Sterk PJ. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996;51:496-502.

19. Kim CK, Choi J, Kim HB, Callaway Z, Shin BM, Kim JT, Fujisawa T, Koh YY. A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation. J Pediatr 2010;156:749-54.
20. KleinJan A, Vinke JG, Severijnen LW, Fokkens WJ. Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients. Eur Respir J 2000;15:491-7. 

21. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, Kay AB, Rothenberg ME. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008;38:709-50.

22. Grossman J. One airway, one disease. Chest 1997;111:11S-6S.

23. Agondi RC, Machado ML, Kalil J, Giavina-Bianchi P. Intranasal corticosteroid administration reduces nonspecific bronchial hyperresponsiveness and improves asthma symptoms. J Asthma 2008;45:754-7.

24. Zhang H, Chen X, Wang HW, Xiang YB. [Treatment of allergic rhinitis with asthma by different ways of inhaling corticosteroids]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2009;44:16-20. (Chinese).

25. Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2017;8:CD005603.

26. Gleich GJ, Adolphson CR. The eosinophilic leukocyte: structure and function. Adv Immunol 1986;39:177-253.